Paclitaxel-induced dorsal hand-foot syndrome.
Quan EY, Engel C, Rush PS, Eikenberg JD.
Dermatol Online J. 2023 Jun 15;29(3). doi: 10.5070/D329361434.
Crossed cheiro-oral syndrome.
Chen WH, Li TH, Chen TH, Lin HS, Hsu MC, Chen SS, Liu JS.
Clin Neurol Neurosurg. 2008 Dec;110(10):1008-11. doi: 10.1016/j.clineuro.2008.06.013. Epub 2008 Jul 30.
12. Vascular pain: Ischemic pain in the extremities and Raynaud's syndrome.
van der Gaag A, Cohen SP, Stojanovic MP, Huygen FJPM, Kallewaard JW.
Pain Pract. 2024 Sep 30;25(1):e13421. doi: 10.1111/papr.13421. Online ahead of print.
Acral dysesthesia and trastuzumab (Herceptin).
O'Brien TJ.
Australas J Dermatol. 2004 Aug;45(3):195-6. doi: 10.1111/j.1440-0960.2004.00091.x.
Neuropeptidergic acral dysesthesia: a new entity.
Lotti T, Tsampau D, Teofoli P, Benci M, Ghersetich I, Dahm M, Cappugi P, Panconesi E.
Int J Dermatol. 1993 Mar;32(3):198-9. doi: 10.1111/j.1365-4362.1993.tb02793.x.
Small fiber pathology--a culprit for many painful disorders?
Üçeyler N.
Pain. 2016 Feb;157 Suppl 1:S60-S66. doi: 10.1097/j.pain.0000000000000411.
Management of Paclitaxel-induced hand-foot syndrome.
Assi HA, Ayoub ZA, Jaber SM, Sibai HA, El Saghir NS.
Breast Care (Basel). 2013 Jun;8(3):215-7. doi: 10.1159/000352097.
Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.
Lipworth AD, Robert C, Zhu AX.
Oncology. 2009;77(5):257-71. doi: 10.1159/000258880. Epub 2009 Nov 16.
Oral hyperpigmentation as an initial clinical aspect of hand foot syndrome.
Santos-Leite ÉGD, Sacramento LV, Santana AM, Dantas JBL, Carrera M, Martins GB.
Braz Dent J. 2022 Jul-Aug;33(4):97-102. doi: 10.1590/0103-6440202204711.
Bullous acral erythema: an additional consideration in the differential diagnosis of pauci-inflammatory subepidermal bullae*.
Podjasek JO, Camilleri MJ.
J Cutan Pathol. 2012 Mar;39(3):382-90. doi: 10.1111/j.1600-0560.2012.01867.x.
